NeOnc Technologies has received FDA authorization to advance into Phase IIa/IIb of its NEO212-01 clinical trial for brain cancer treatment.
The Phase I dose-escalation study showed that NEO212 could be safely administered at doses up to 810 mg daily on specific days.
NEO212 combines Temozolomide with NEO100, aiming to enhance blood-brain barrier penetration and antitumor activity, potentially replacing the current standard of care for brain cancers.
Next-Generation Candidate
NEO212 is NeOnc's innovative oral chemical conjugated chemotherapy drug, merging Temozolomide with NEO100, offering improved efficacy and potential as a new standard of care for brain cancers.
Phase II Clinical Development
The Phase II trial will expand patient enrollment across leading U.S. cancer centers, potentially changing the future of brain cancer treatment worldwide.
Leadership Commentary
Amir Heshmatpour, Executive Chairman, and Dr. Thomas Chen, CEO, expressed optimism and commitment to revolutionize brain cancer treatment with NEO212.
- FDA authorization marks a significant milestone for NeOnc, paving the way for advanced clinical trials and potential breakthroughs in brain cancer treatment.
- NEO212's unique composition and promising results suggest a transformative shift in the standard of care for brain cancers, offering new hope to patients and families.
NeOnc's groundbreaking NEO212 treatment, authorized for Phase II trials, signifies a remarkable advancement in brain cancer therapeutics, reflecting the company's dedication to innovation and patient care.